Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Base de dados
Tipo de documento
País/Região como assunto
Intervalo de ano de publicação
1.
Dermatol Ther ; 34(2): e14793, 2021 03.
Artigo em Inglês | MEDLINE | ID: mdl-33480148

RESUMO

The use of combined systemic retinoids and intralesional immunotherapy in the management of warts is still debatable without straightforward evidence. Through network meta-analysis, the current study evaluated the efficacy and safety of systemic retinoids alone or combined with other remedies in the treatment of warts. We searched six literature databases for clinical trials that compared systemic retinoids to local treatments or placebo in wart management. Outcomes were calculated as odds ratios (OR) with 95% confidence-interval. We used the R software to perform conventional and network meta-analyses (with a frequentist approach). Network meta-analysis of eight trials showed that oral acitretin plus intralesional Candida Ag (OR = 367.71), INF-α plus oral isotretinoin (OR = 223.77), oral acitretin (OR = 117), Candida Ag (OR = 91.93), oral isotretinoin (OR = 62.26) and topical isotretinoin (OR = 17.69) had higher complete recovery rates than placebo. Regarding the P-score, oral acitretin plus intralesional Candida Ag had the highest efficacy in achieving complete response (P-score = 0.88), followed by INF-α plus oral isotretinoin (P-score = 0.79), then oral acitretin (P-score = 0.60). Variable baseline characteristics and lack of data on some outcomes. The current study shows the efficacy for systemic retinoids in the treatment of warts, especially reluctant or recurrent types. Moreover, combinations of systemic retinoids with intralesional immunotherapy yield higher rates of complete clearance with lower recurrence.


Assuntos
Verrugas , Acitretina/efeitos adversos , Humanos , Imunoterapia , Isotretinoína/efeitos adversos , Metanálise em Rede , Verrugas/tratamento farmacológico
2.
Dermatol Ther ; 33(6): e13992, 2020 11.
Artigo em Inglês | MEDLINE | ID: mdl-32648324

RESUMO

Two round tables involving experts were organized in order to reach a consensus on the management of patients with actinic keratosis (AK). In the first, seven clinical questions were selected and analyzed by a systematic literature review, using a Population, Intervention, Control, and Outcomes framework; in the second, the experts discussed relevant evidences and a consensus statement for each question was developed. Consensus was reached among experts on how to best treat AK patients with respect to different clinical scenarios and special populations. Lesion-directed treatments are preferred in patients with few AKs. Patients with multiple AKs are challenging, with more than one treatment usually needed to achieve complete lesion clearance or a high lesion response rate, therapy should be personalized, based on previous treatments, patient, and lesion characteristics. Methyl aminolevulinate-PDT, DL (day light) PDT, and imiquimod cream were demonstrated to have the lowest percentage of new AKs after post treatment follow-up. For IMQ 5% and 3.75%, a higher intensity of skin reactions is associated with higher efficacy. Photodynamic therapy (PDT) is the most studied treatment for AKs on the arms. Regular sunscreen use helps preventing new AKs. Oral nicotinamide 500 mg twice daily, systemic retinoids and regular sunscreen use were demonstrated to reduce the number of new squamous cell carcinomas in patients with AKs. Limited evidence is available for the treatment of AKs in organ transplant recipients. There is no evidence in favor or against the use of any of the available treatments in patients suffering from hematological cancer.


Assuntos
Ceratose Actínica , Fotoquimioterapia , Ácido Aminolevulínico/uso terapêutico , Consenso , Humanos , Itália , Ceratose Actínica/diagnóstico , Ceratose Actínica/tratamento farmacológico , Fármacos Fotossensibilizantes/efeitos adversos , Resultado do Tratamento
3.
Dermatol Ther ; 28(6): 366-8, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26133643

RESUMO

We present a case of a 63-year old man with severe chronic plaque psoriasis and a recent history of lung cancer, wherein fever appeared suddenly after initiation of treatment with low dose acitretin. Tumor recurrence or infection was not found during extensive examinations, nevertheless the patient was empirically treated with broad-spectrum antibiotics without any effect on fever. Immediately after discontinuation of acitretin therapy, the fever disappeared. The patient was followed for next 2 years, during this period similar problems did not reappear, although there has been a relapse of psoriasis and the patient was switched later on biological treatment.


Assuntos
Acitretina/efeitos adversos , Febre/induzido quimicamente , Ceratolíticos/efeitos adversos , Psoríase/tratamento farmacológico , Substituição de Medicamentos , Febre/diagnóstico , Humanos , Masculino , Pessoa de Meia-Idade , Psoríase/diagnóstico , Resultado do Tratamento
4.
Dermatologie (Heidelb) ; 73(8): 634-637, 2022 Aug.
Artigo em Alemão | MEDLINE | ID: mdl-35296923

RESUMO

Numerous cutaneous side effects associated with COVID-19 vaccines have been described since their clinical approval. These include, among others, injection site reactions, urticarial, maculopapular and pityriasiform rashes or temporary exacerbations of a pre-existing chronic inflammatory skin disease. Herein we report about three cases of pityriasis rubra pilaris that occurred for the first time in close temporal relationship with the administration of a COVID-19 vaccine.


Assuntos
Vacinas contra COVID-19 , COVID-19 , Pitiríase Rubra Pilar , COVID-19/prevenção & controle , Vacinas contra COVID-19/efeitos adversos , Humanos , Pitiríase Rubra Pilar/induzido quimicamente , Pele , Vacinação/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA